EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access

Tenofovir Douche as HIV Preexposure Prophylaxis for Receptive Anal Intercourse: Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics (DREAM 01)

Ethel D Weld iD, Ian McGowan, Peter Anton, Edward J Fuchs, Ken Ho, Alex Carballo-Dieguez, Lisa C Rohan, Rebecca Giguere, Rhonda Brand, Stacey Edick, Rahul P Bakshi, Teresa Parsons und 13 weitere

The Journal of Infectious Diseases · 12.04.2024 · 229 (4) · 1131-1140

DOI: 10.1093/infdis/jiad535 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 29.11.2023. Verfasst von Ethel D Weld und 24 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Adenine, Anti-HIV Agents, Colorectal Neoplasms, HIV Infections. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIGMS NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite highly effective HIV preexposure prophylaxis (PrEP) options, no options provide on-demand, nonsystemic, behaviorally congruent PrEP that many desire. A tenofovir-medicated rectal douche before receptive anal intercourse may provide this option.

Methods

Three tenofovir rectal douches—220 mg iso-osmolar product A, 660 mg iso-osmolar product B, and 660 mg hypo-osmolar product C—were studied in 21 HIV-negative men who have sex with men. We sampled blood and colorectal tissue to assess safety, acceptability, pharmacokinetics, and pharmacodynamics.

Results

The douches had high acceptability without toxicity. Median plasma tenofovir peak concentrations for all products were several-fold below trough concentrations associated with oral tenofovir disoproxil fumarate (TDF). Median colon tissue mucosal mononuclear cell (MMC) tenofovir-diphosphate concentrations exceeded target concentrations from 1 hour through 3 to 7 days after dosing. For 6–7 days after a single product C dose, MMC tenofovir-diphosphate exceeded concentrations expected with steady-state oral TDF 300 mg on-demand 2-1-1 dosing. Compared to predrug baseline, HIV replication after ex vivo colon tissue HIV challenge demonstrated a concentration-response relationship with 1.9 log10 maximal effect.

Conclusions

All 3 tenofovir douches achieved tissue tenofovir-diphosphate concentrations and colorectal antiviral effect exceeding oral TDF and with lower systemic tenofovir. Tenofovir douches may provide a single-dose, on-demand, behaviorally congruent PrEP option, and warrant continued development. Clinical Trials Registration . NCT02750540.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenineAnti-HIV AgentsColorectal NeoplasmsHIV InfectionsOrganophosphatesPre-Exposure ProphylaxisSexual and Gender MinoritiesHumansMaleDiphosphatesEmtricitabineHomosexuality, MaleTenofovir

Stichwörter der Autor:innen

HIVmicrobicidepharmacodynamicspharmacokineticsphase 1preexposure prophylaxis

Substanzen

AdenineAnti-HIV AgentsDiphosphatesEmtricitabineOrganophosphatesTenofovirtenofovir diphosphate

Autor:innen und Institutionen

  • Division of Clinical Pharmacology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Orion Biotechnology, Ottawa, Ontario, Canada.
  • Division of Gastroenterology, Department of Medicine, University of California Los Angeles, Los Angeles, California, USA.
  • HIV Center for Clinical and Behavioral Studies, Columbia University and NewYork State Psychiatric Institute, New York, New York, USA.

ORCID-Profile: Ethel D Weld, Craig W Hendrix

Förderung

  • NIAID NIH HHS
  • NIGMS NIH HHS
  • NIH HHS
  • National Institutes of Health
  • Department of Allergy and Infectious Disease
  • Division of AIDS
  • Center for AIDS Research
  • Johns Hopkins University

Zitieren

APA

Weld, E. D., McGowan, I., Anton, P., Fuchs, E. J., Ho, K., Carballo-Dieguez, A., Rohan, L. C., Giguere, R., Brand, R., Edick, S., Bakshi, R. P., Parsons, T., Manohar, M., Seigel, A., Engstrom, J., Elliott, J., Jacobson, C., Bagia, C., Wang, L., …, & Hendrix, C. W. (2024). Tenofovir Douche as HIV Preexposure Prophylaxis for Receptive Anal Intercourse: Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics (DREAM 01). The Journal of Infectious Diseases, 229(4), 1131-1140. https://doi.org/10.1093/infdis/jiad535

Vancouver

Weld ED, McGowan I, Anton P, Fuchs EJ, Ho K, Carballo-Dieguez A, et al. Tenofovir Douche as HIV Preexposure Prophylaxis for Receptive Anal Intercourse: Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics (DREAM 01). The Journal of Infectious Diseases. 2024;229(4):1131-1140. doi:10.1093/infdis/jiad535

BibTeX
@article{Weld2024,
  author = {Weld, Ethel D and McGowan, Ian and Anton, Peter and Fuchs, Edward J and Ho, Ken and Carballo-Dieguez, Alex and Rohan, Lisa C and Giguere, Rebecca and Brand, Rhonda and Edick, Stacey and Bakshi, Rahul P and Parsons, Teresa and Manohar, Madhuri and Seigel, Aaron and Engstrom, Jared and Elliott, Julie and Jacobson, Cindy and Bagia, Christina and Wang, Lin and Al-Khouja, Amer and Hartman, Douglas J and Bumpus, Namandje N and Spiegel, Hans M L and Marzinke, Mark A and Hendrix, Craig W},
  title = {Tenofovir Douche as HIV Preexposure Prophylaxis for Receptive Anal Intercourse: Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics (DREAM 01)},
  journal = {The Journal of Infectious Diseases},
  year = {2024},
  volume = {229},
  number = {4},
  pages = {1131--1140},
  doi = {10.1093/infdis/jiad535}
}
Kostenlos starten →